The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DL CO ), and chest-CT were performed at 23 Norwegian hospitals included in the NOR-SOLIDARITY trial, an open-labelled, randomised clinical trial, investigating the efficacy of remdesivir and hydroxychloroquine (HCQ). Thirty-eight percent had a CAT-score ≥ 10. DL CO was below the lower limit of normal in 29.6%. Ground-glass opacities were present in 39.8% on chest-CT, parenchymal bands were found in 41.7%. At admission, low pO 2 /F i O 2 ratio, ICU treatment, high viral load, and low antibody levels, were predictors of a poorer pulmonary outcome after 3 months. High levels of matrix metalloproteinase (MMP)-9 during hospitalisation and at 3 months were associated with persistent CT-findings. Except for a negative effect of remdesivir on CAT-score, we found no effect of remdesivir or HCQ on long-term pulmonary outcomes. Three months after hospital admission for COVID-19, a high prevalence of respiratory symptoms, reduced DL CO , and persistent CT-findings was observed. Low pO 2 /F i O 2 ratio, ICU-admission, high viral load, low antibody levels, and high levels of MMP-9 were associated with a worse pulmonary outcome.
【저자키워드】 Respiratory distress syndrome, viral infection, Predictive markers, Antimicrobial responses, 【초록키워드】 COVID-19, Efficacy, clinical trial, Trial, randomised, Hydroxychloroquine, antibody, disease severity, hospital, Remdesivir, lung, spirometry, outcome, COPD, Prevalence, outcomes, Viral, Ground-glass opacities, Viral load, Lungs, Patient, Hospital admission, HCQ, predictor, respiratory, hospitalisation, Admission, association, marker, respiratory symptoms, mediators, except for, no effect, diffusion capacity, matrix metalloproteinase, high viral load, ICU treatment, limit, performed, reduced, parenchymal, pro-fibrotic, 【제목키워드】 COVID-19, Antibody Response, Viral load, persistent, Pulmonary pathology,